These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12434521)

  • 1. The multiple actions of selegiline.
    Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L
    Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R; Ebadi M; Pfeiffer RF
    Neurosci Lett; 1995 Nov; 200(2):77-80. PubMed ID: 8614567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
    McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
    Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 6. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
    Sanz E; Romera M; Bellik L; Marco JI; Unzeta M
    Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G
    J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
    Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
    Mytilineou C; Radcliffe PM; Olanow CW
    J Neurochem; 1997 Jan; 68(1):434-6. PubMed ID: 8978757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P
    Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
    Pálfi M; Szökó E; Kálmán M
    Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of selegiline hydrochloride on intracellular Ca2+ contents in cultured neuronal cells].
    Itoh T; Takahata K; Morimoto K; Iwamoto N; Ohde H
    No To Shinkei; 1998 Dec; 50(12):1093-9. PubMed ID: 9989354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective and neuronal rescue effects of selegiline: review.
    Magyar K; Haberle D
    Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF
    Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The early therapy challenge].
    Reichmann H
    Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.